NCT04341311 2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
9 trialsNCT00667862 2021-06-21
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT00503451 2020-12-19
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00570284 2020-12-19
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00739414 2020-12-19
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00939159 2018-08-23
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00632489 2015-06-08
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00891033 2015-02-23
Panobinostat/Velcade in Multiple Myeloma
University of Arkansas
Phase 1 Terminated
NCT00412997 2012-11-27
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Novartis
Phase 1 Completed